Introduction
Programmed cell death, also called apoptosis, plays a critical role in the regulation of cell survival and death.
1,2 Apoptosis can be induced by removal of growth factors, by triggering of specific cell-surface molecules, and by DNA-damaging agents such as ionizing radiation and chemotherapeutic drugs. [3] [4] [5] [6] Response to these apoptotic inducers varies considerably in both normal and neoplastic cells. Central to this response are regulatory proteins that modulate apoptosis, including the p53 and Bcl-2 gene products. The p53 tumor suppressor protein in its wild-type but not mutant conformation is an apoptotic effector, whereas Bcl-2 acts as a repressor of apoptosis. 7, 8 Fas (APO-1/CD95) is a cell-surface protein that mediates apoptosis in susceptible cells upon binding by its ligand or anti-Fas antibody. 9, 10 Fas-mediated apoptosis plays an important role in developmental cell elimination, regulation of the immune system, and T cell-mediated cytotoxicity. [11] [12] [13] [14] Cross-linking of Fas by anti-Fas antibodies causes apoptosis in certain hematopoietic malignancies, suggesting a possible therapeutic role for anti-Fas antibody. [15] [16] [17] However, not all Fas+ cells are susceptible to anti-Fas. For instance, a recent study of a large series of acute lymphoblastic leukemia (ALL) patients demonstrated that Fas antigen was expressed in most ALL cases, while only 5% of Fas+ cases were susceptible to apoptosis triggered by anti-Fas antibody. 18 The mechanisms by which Fas+ cells are resistant to antiFas-induced apoptosis are not well understood; in particular, the role of Bcl-2 in Fas-mediated apoptosis has been controversial. Some studies have shown that the Fas-resistant phenotype is linked to overexpression of Bcl-2 in primary leukemic cells, 19, 20 and experimental down-regulation of Bcl-2 or introduction of ectopic Bcl-2 into Bcl-2-negative leukemic cell lines increases or decreases their susceptibility to Fasmediated apoptosis, respectively. 19, 21 In other studies, however, no correlation was found between Bcl-2 expression and susceptibility to Fas-mediated cytotoxicity. 18, 22 Furthermore, the role of p53 as a possible modulator of Fas expression and function is uncertain. Experimental overexpression of ectopic wt-p53 in non-small-cell lung cancer and an erythroleukemic cell line led to the up-regulation of Fas. 23 However, p53-deficient mice express functional Fas in all hematopoietic cell lineages. 24 In addition, Fas is expressed in most myeloma cell lines with p53 mutations, and treatment of these Fas+/mt-p53+ cells with anti-Fas antibody induced apoptosis, suggesting that Fas-mediated apoptosis is independent of wt-p53 regulation. 25 In the present study, we found that pediatric ALL cells with a point mutation in exon-7 of p53 (codon 248) tended to express higher levels of Fas and greater Fas sensitivity than did wt-p53+ cells, which were generally Fas-resistant. Resistance to Fas was also associated with increased expression of Bcl-2, which was generally absent in mt-p53+ cells.
Materials and methods

Cell lines and primary leukemic cells
Twenty-five cell lines established from children with ALL were studied. Fourteen of these lines (EU-1 to EU-13 and EU-18) were established at Emory University, and nine (UoC-B1, UoC-B3, UoC-B4, UoC-B11, SUP-B2, SUP-B7, SUP-B13, SUP-B15, KT) were obtained from Stephen D Smith (University of Chicago Medical Center, Chicago, IL, USA). The Reh ALL line was obtained from C Rosenfeld (INSERM, Villejuif, France), and CCRF-CEM was obtained from the American Type Culture Collection (Rockville, MD, USA). The phenotypes of these lines are summarized in Table 1 and in previous publications. [26] [27] [28] All lines were grown in RPMI 1640 containing 10% fetal bovine serum, 2 mM L-glutamine, 50 units penicillin and 50 g/ml streptomycin.
Bone marrow samples were obtained from patients during routine diagnostic procedures following informed consent. Leukemic cells were enriched by Ficoll-Hypaque (1.077 g/ml) centrifugation, and aliquots were either cultured to establish the cell lines or cryopreserved in 10% DMSO. The diagnosis and classification of the leukemias were based on immunophenotypic, cytochemical, and morphologic criteria of the Pediatric Oncology Group and the French-American-British system.
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Table 1
Expression of Fas and susceptibility to Fas-mediated CPP32 protease activation and apoptosis in ALL cell lines: association with p53 mutations and Bcl-2 expression 
Flow cytometric analysis
Cell-surface expression of the Fas antigen and Bcl-2 protein expression were measured by flow cytometry. Fas was detected using FITC-labeled mouse anti-human Fas antibody, which does not induce apoptosis. FITC-conjugated irrelevant mouse IgG1 antibody was used as a negative control to determine background fluorescence. Cells (10 6 ) were incubated with anti-Fas or control antibody for 30 min at 4°C. After washing twice, the cells were fixed in PBS containing 1% paraformaldehyde (pH 7.0) prior to analysis. Bcl-2 protein expression was analyzed by the method of Aiello et al 30 using 70% cold methanol fixation followed by anti-Bcl-2 or isotypematched control antibody and FITC-conjugated mouse anti-hamster IgG antibody (Pharmingen). Immunoflurescence (IF) analysis was performed in a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) using CellQuest software (Becton Dickinson). Mean fluorescence intensity of Fas-FITC and Bcl-2-FITC was detected using a logarithmic scale and converted into number of molecules of equivalent soluble fluorochrome per cell (MESF value) by comparison with calibrated fluorescent-bead reference standards (Rainbow Calibration Beads; Pharmingen). These fluorescence standards were analyzed in parallel with the stained cells using identical flow-cytometric settings. Negative controls consisted of isotope-matched irrelevant antibody, and control MESF values were subtracted to calculate net MESF values for the cell lines.
Single-strand conformation polymorphism (SSCP) analysis and DNA sequencing
Genomic DNA was prepared from each sample using a DNA Isolation Kit (Puregene, Minneapolis, MN, USA) following the manufacturer's instructions. p53 exons 5-8, which are commonly mutated in tumor cells, were analyzed for point mutations by SSCP as described in our previous study. 28 Briefly, genomic DNA (100 ng) was subjected to PCR amplification using 10 pmol of each primer, 2.5 M dNTPs, 1 Ci of alpha-32 P dCTP and 0.5 unit of Taq polymerase in a buffer containing 10 mM Tris HCl (pH 8.8), 50 mM KCl, 1 mM MgCl 2 and 0.01% gelatin. Thirty cycles of denaturation (94°C), annealing (55°C) and extension (72°C) were performed in an automated heat-block. PCR products were electrophoresed in a 6% acrylamide/TBE gel containing 5% (v/v) glycerol. Gels were run at 8 W for 12-15 h at room temperature. Autoradiography was performed for 6-24 h. PCR products that demonstrated an aberrant migration pattern in the SSCP autoradiograph relative to the wild-type gene were analyzed for nucleotide sequence. Before sequencing, the targeted DNA was amplified with 1 g of genomic DNA and 50 pmol of each primer in a final volume of 100 l. The conditions and number of cycles of PCR were as described for the SSCP analysis, omitting the 32 P-dCTP. The PCR products were separated by electrophoresis in an agarose gel and purified using the DNA Purification System (Promega, Madison, WI, USA). Purified cDNA was sequenced using a modification of the dideoxy chain-termination procedure (Double-stranded DNA Cycle Sequencing System; Life Technologies, Gaithersburg, MD, USA) following the manufacturer's recommendations.
DNA fragmentation analysis
Apoptosis was determined by DNA fragmentation assay. DNA was prepared from each sample using a DNA Isolation Kit (Puregene). DNA from 5 × 10 5 cells was resolved by electrophoresis on a 1.5% agarose gel containing ethidium bromide, and DNA fragments were visualized under UV light.
CPP32 protease assay
The CPP32 protease activation after treatment with anti-Fas antibody was detected with a CPP32 protease assay kit (Clontech, Palo Alto, CA, USA). Briefly, treated and untreated cells (2 × 10 6 ) were pelleted, resuspended in 50 l lysis buffer and incubated on ice for 10 min. Fifty microliters of 2 × reaction buffer (containing DTT) was then added to the cell lysate and incubated with conjugated substrate (DEVD-pNA, 50 M final concentration) at 37°C for 1 h, at which time the concentration of the chromogenic cleavage product (p-nitroanilide, pNA) was determined by spectrophotometry at 405 nm. Protease activity was expressed as fold-increase in cleavage product relative to the untreated control. Assay specificity was evaluated by adding to the reaction a peptide (DQED) that specifically inhibits CPP32 activity; no significant background absorbance was detected in assays containing the inhibitor.
Western blot assay
Cells were lysed in a buffer composed of 150 mM NaCl, 50 mM Tris (pH 8.0), 5 mM EDTA, 1% (v/v) Nonidet p-40, 1 mM phenylmethylsulfonyl fluoride, 20 g/ml aprotinin, and 25 g/ml leupeptin for 30 min at 4°C. After clarification, equal amounts of protein extracts were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose paper. After blocking with buffer containing 20 mM Tris-HCl (pH 7.5) and 500 mM NaCl, 5% non-fat milk for 1 h at room temperature, filters were incubated with specific antibodies for 1 h at room temperature followed by HRP-labeled secondary antibody. Blots were developed using a chemiluminescent detection system (ECL, Amersham Life Science, Buckinghamshire, UK).
Results
p53 mutations in ALL cells
The results of p53 point mutations in ALL cell lines are summarized in Table 1 and representative results for SSCP analysis are shown in Figure 1 . p53 mutations in codon 248 (lines EU-
Figure 1
SSCP analysis of p53 mutations in ALL cell lines. Radiolabeled PCR-amplified genomic DNA fragments corresponding to exon 7 (upper) and exon 8 (lower) were denatured and separated on a 6% acrylamide/5% glycerol gel. Gels were run at 8 W for 12-15 h at room temperature and autoradiographed. Arrows indicate DNA fragments containing point mutations.
2, EU-7 and CCRF-CEM) and codon 273 (EU-6) were reported in our previous study. 28 Additionally, exon-7 mutations in codon 248 were detected in three more recently established lines (EU-10, EU-11 and EU13), while EU-18 showed an abnormal migration pattern in exon 8 and had a codon 273 mutation (Figure 2) . Thus, the overall frequency of p53 mutations among the pediatric ALL lines studied was 32% (8/25); however, p53 mutations were more frequent in T-ALL (50%, 2/4) than in B cell precursor (BCP)-ALL (28%, 6/21). All 25 lines had normal PCR-SSCP patterns for exons 5 and 6 of the p53 gene (data not shown). Furthermore, we detected identical mutations of p53 in the primary bone marrow leukemic cells from which EU-10, EU-11 and EU-18 were established (data not shown).
Expression of Fas antigen and Bcl-2 protein in ALL cells
We examined Fas expression by FACS analysis; results for the cell lines are summarized in Table 1 . Representative fluorescence histograms are shown in Figure 3 . Levels of fluorescence intensity were calculated by comparison with calibrated fluorescent-bead reference standards and were expressed as MESF. When less than 150 MESF was defined as negative, 13/25 cell lines were positive for Fas antigen (10 of 21 BCP-ALL and three of four T-ALL). Elevated levels of Fas were expressed in all six lines with mutations of p53 in codon 248 (1500 to 10 800 MESF), and two lines with mutations in codon 273 did not express Fas. Although Fas was detected in seven of the 17 lines without p53 mutation, expression was lower (150-900 MESF) compared with mt-p53+ lines.
We have previously reported the results of Bcl-2 expression in 22 of the 25 lines detected by Northern blot and Western blot analysis. 31 In the present study, we have further examined Bcl-2 expression by flow cytometry and quantitated the protein (expressed as MESF) in the Fas+ lines as well as in three recently established mt-p53+ lines (EU-10, EU-11 and EU-18). Results of Bcl-2 expression detected by either flow cytometry or Northern blot assay were consistent, and EU-10, EU-11 and EU-18 were negative for Bcl-2 (Table 1 and Figure 4) . Altogether, significant levels of Bcl-2 were detected in 10 of the 25 lines (10 of 21 BCP-ALL and none of four T-ALL). Most (nine of 10) wt-p53+ lines expressed Bcl-2, whereas most (seven of eight) mt-p53+ and all p53-null ALL lines were negative for this protein. Furthermore, we compared Bcl-2 and Fas
Figure 2
Sequence analysis of p53 mutations in ALL cell lines. Sequences from exon 7 for cell lines EU-10, EU-11 and EU-13 show the same point mutation in codon 248. Sequence from exon 8 is shown for cell line EU-18. Arrows point to bands corresponding to mutated base pairs. 
Figure 4
Fluorescence histograms of Bcl-2 protein expression for ALL cell lines detected by flow cytometric analysis. Cells were stained with anti-human Bcl-2 antibody (bold lines) or a hamster IgG-isotype antibody as a negative control (fine lines), followed by a FITC-conjugated secondary antibody. Data for representative wt-p53+ and mtp53+ ALL lines are shown.
expression by primary leukemic cells and by derived cell lines for five cases in which cryopreserved primary cells were available. Identical results were obtained for cell lines and primary leukemic cells in each case (Table 2) . 
Figure 5
Agarose-gel electrophoresis pattern obtained with DNA extracted from Fas+ ALL lines (Reh→EU-9, Fas+/wt-p53+; EU-2→CCRF-CEM, Fas+/mt-p53+; EU-6, Fas−/mt-p53+ (as control). Cells were treated with anti-Fas (200 ng/ml) for 6 h; untreated cells served as a control. Molecular size markers (M) are shown on right.
Sensitivity to anti-Fas antibody-induced apoptosis
To determine the sensitivity of Fas+ ALL cell lines to Fasinduced apoptosis, cells were treated with anti-Fas monoclonal antibody (200 ng/ml) for 6 h. Characteristic DNA ladder formation was observed in eight of the 13 Fas-positive ALL cell lines. Six of eight Fas+/Fas-sensitive (S) lines were mt-53+, whereas only 2 Fas+/Fas-S lines were wt-p53+; both of these latter lines showed much less DNA fragmentation than the Fas+/mt-p53+ lines ( Figure 5 ). All six Fas+/wt-p53+ lines expressed Bcl-2. Resistance to Fas-mediated apoptosis in four of these lines was associated with increased Bcl-2 expression (MESF Ͼ1000; median, 4750; mean, 5560) ( Table 1 ). In contrast, two Fas+/wt-p53+ lines (UoC-B4 and EU-3) that were sensitive to Fas-mediated apoptosis expressed low levels of Bcl-2 (MESF 425 and 680, respectively). Unlike the Fas+/wtp53+ lines, all Fas+/mt-p53+ lines were negative for Bcl-2; these lines were sensitive to Fas-mediated apoptosis. One mtp53 line (EU-6) expressed high levels of Bcl-2 but lacked expression of Fas, while a second Fas−/mt-p53+ line (EU-18) did not express Bcl-2. None of the p53-null lines expressed Bcl-2, and only one of these lines (EU-9) was Fas+; this line expressed a low level of Fas and was resistant to treatment with anti-Fas antibody. Significantly, similar results were obtained for both primary leukemic cells and the corresponding cell lines in five cases studied (Table 2) .
Fas-induced CPP32 activation and PARP degradation
To determine whether Fas-induced apoptosis is associated with activation of the cysteine protease cascade in ALL cells, we examined CPP32 activation and PARP degradation in Fas+ ALL cell lines. CPP32 activation was examined by colorimetric assay in 17 of the 25 lines including 13 Fas+ lines following treatment with anti-Fas antibody. As summarized in Table 1 , significant activation of CPP32 (Ͼ2 fold-increase in pNA cleavage product) was observed in eight of 13 Fas+ lines and none of four Fas-lines tested. Figure 6 shows characteristic kinetics for CPP32 activation observed with Fas+/mtp53+/Bcl2-ALL cells (EU-2) following treatment with anti-Fas antibody. CPP32 activity reached a peak at 8-12 h post-treatment and then decreased after 12 h. The degree of CPP32 acti-
Figure 6
Activation of CPP32 protease detected in ALL cell lines EU-2 (Fas+/mt-p53+/Bcl-2−) and EU-1 (Fas+/wt-p53+/Bcl-2+) after treatment with anti-Fas antibody. Cells were treated with different concentrations of anti-Fas antibody for 6 h (a) or with 200 ng/ml of anti-Fas for the indicated times (b). The activity of CPP32 was determined by a colorimetric assay to detect the chromophore p-nitroanilide (pNA) after cleavage from the labeled DEVD-pNA using a CPP32 assay kit. The results are presented as fold-stimulation by comparing treated cells with untreated cells. Each point represents the mean ± s.d. of three separate experiments. As a control for specificity, a CPP32 inhibitor (peptide DQVD) was added to the treated EU-2 cells before incubation with the substrate.
vation was proportional to the concentration of anti-Fas antibody. When a specific, noncleavable inhibitor of CPP32 function (peptide DQED) was added in the above assay, there was no increase in pNA cleavage product, indicating that specific CPP32 activation was detected following addition of antiFas antibody. Figure 7 shows activation of CPP32 in EU-2 cells (represented by appearance of the 20 kDa cleavage product in the Western blot); simultaneously, cleavage of PARP (the substrate for CPP32) was also observed, represented by the appearance of the 85 kDa PARP cleavage product. These Fas-induced cleavages of CPP32 and PARP were not observed in the EU-1 (Fas+/wt-p53+/Bcl-2+) line.
Discussion
In this study, we examined the expression and function of Fas in a large group of pediatric ALL cell lines to evaluate the role of p53 and Bcl-2 in possibly modulating Fas-mediated apoptosis. The majority of these lines were derived from patients with either BCP-ALL or T-ALL at relapse who had developed refractory disease and failed to respond to reinduction therapy. These patients are characterized by an increased incidence of p53 mutations compared to patients at initial diagnosis, as reflected in the phenotypes of the derived lines. 32 Two of these lines (EU-10 and 11) were unusual in that they were established from patients with BCP-ALL at diagnosis whose leukemic cells expressed a mutant p53 gene, which occurs in Ͻ10% of B-lineage ALL patients at diagnosis. 32 We have found that many of these mutant-p53 lines are resistant to apoptosis following treatment with either ionizing radiation (IR) or doxorubicin, as were the primary cells from which these lines were established (Ref. 31 and the authors' unpublished data). Furthermore, since several of these lines express Bcl-2 as well as Fas, they provide an opportunity to study the relationship between p53 phenotype, Bcl-2 expression, and susceptibility to Fas-mediated apoptosis.
As we have previously noted, pediatric ALL lines expressing wt-p53 have an increased frequency of elevated Bcl-2 expression compared to mt-p53 lines; furthermore, basal levels of Bcl-2 expression per se are not predictive of resistance
Figure 7
Western blot analysis of the cleavage of CPP32 and its substrate PARP in ALL cell lines EU-1 and EU-2 treated with anti-Fas antibody. Cells were incubated for 6 h with the indicated concentrations of anti-Fas. Protein (10 g) from cell lysates was electrophoresed in SDS-PAGE gel, transferred to nitrocellulose, and probed with anti-CPP32 and anti-PARP antibodies. Anti-CPP32 recognized both the 32 kDa unprocessed pro-protease and the 20 kDa subunit; the 11-12 kDa subunit was not detected. Anti-PARP detected an 85 kDa fragment cleaved from the 116 kDa PARP holenzyme.
to IR and certain chemotherapeutic agents such as doxorubicin. 31, 33 Instead, our data suggest that defective regulation of Bcl-2 and its antagonist Bax in ALL cells following exposure to IR is associated with resistance to IR-induced apoptosis. 31 However, the effect of p53 and Bcl-2 on Fas-induced apoptosis remains unclear. With regard to the interaction between p53 and Fas, introduction of wt-p53 into p53-null tumor cells (eg non-small-cell lung adenocarcinoma) induced a marked up-regulation of Fas and promoted Fas-mediated apoptosis. 23 However, other studies have suggested that Fas is expressed in a p53-independent manner. Thus, in some myeloma and Hodgkin's lymphoma lines with a mt-p53 phenotype, Fas was strongly expressed and capable of inducing apoptosis. 25, 34 Additionally, in their study of p53-deficient mice, Li et al 24 found that Fas was expressed in multiple lineages of hematopoietic precursor cells, suggesting that wt-p53 is not required for Fas expression.
Our findings agree with these latter studies in suggesting that Fas expression and function can occur independently of wt-p53, and furthermore that ALL cells containing a mutant p53 gene and lacking Bcl-2 expression may show increased sensitivity to Fas activation compared to wt-p53+/Bcl-2+ cells. We found that levels of Fas were typically higher for mt-p53+ (in six of eight lines) than for wt-p53+ lines. In particular, Fas levels for all six lines with point mutations of p53 in exon-7 (codon 248) exceeded 1000 MESF (1500-10 800; median, 2750), while levels for wt-p53+ lines were significantly lower (150-900; median, 650). These findings are consistent with a gain-of-function phenotype for this mutation, leading to novel transactivation properties for the derived p53 protein. Similar gain-of-function mutations have been reported by other investigators. Insulin-like growth-factor-1 receptor gene transcription is activated by mutant p53, while it is suppressed by wtp53. 35 Similarly, mutant-but not wt-p53 is able to enhance basic fibroblast growth factor (bFGF) promoter activity in some neoplastic cells, resulting in autocrine production of bFGF by these tumors. 36 Interestingly, both lines with point mutations in exon-8 (codon 273) were Fas-negative, suggesting that not all mutant p53 loci are associated with Fasexpression and sensitivity. Also, a Fas-negative phenotype was identified in five of 11 wt-p53+ lines and five of six p53-null lines, suggesting that elevated Fas expression is more common in ALL cells with specific p53 mutations.
A further finding of the present study was an association between expression of Bcl-2 and sensitivity to Fas. Of six wtp53+/Fas+ lines, four expressed high levels of Bcl-2 and were resistant to Fas, while the two Fas-sensitive lines expressed low levels of Bcl-2. In contrast, all six mt-p53+/Fas+ lines were Bcl-2-negative and Fas-sensitive. The role of Bcl-2 in Fasmediated apoptosis has been controversial. Studies of chronic lymphocytic leukemia and non-Hodgkin's lymphomas have suggested that Bcl-2 promotes resistance to Fas-induced apoptosis. 19, 20 In neoplastic cells constitutively expressing high levels of Bcl-2, down-regulation of Bcl-2 increased susceptibility to Fas following treatment with anti-Fas antibody. 19 Furthermore, overexpression of an ectopic Bcl-2 in a murine lymphoma cell line inhibited Fas-mediated apoptosis. 21 In contrast to the above studies, Karawajew et al 18 and Debatin et al 22 found that the susceptibility of primary ALL cells to anti-Fas was not correlated with Bcl-2 expression. The former study found that in 75% of ALL cases at initial diagnosis, no anti-Fas-specific apoptosis could be detected. However, interpretation of these findings was complicated by the presence of high levels of spontaneous apoptosis in untreated cultures of primary ALL cells; significant degrees of spontaneous apoptosis (Ͼ25%) were observed by flow cytometry in 79% of B-lineage and 92% of T-lineage cases. This high background of spontaneous apoptosis was obviated in the present study by the use of ALL cell lines, in which the degree of apoptosis as well as levels of Bcl-2 and Fas expression can be reproducibly quantitated with negligible background.
Our data suggest that expression of high levels of Bcl-2, as seen in the majority of wt-p53+ ALL cells studied, is associated with resistance to Fas-mediated apoptosis, whereas a mt-p53 phenotype and low-level expression of Bcl-2 may be associated with increased sensitivity to Fas. This observation may partly explain the lack of Fas-mediated apoptosis observed in studies with primary ALL cells at diagnosis. As shown by other studies, Ͼ90% of B-lineage and T-lineage ALL cases at diagnosis have a wt-p53+ phenotype and generally express high levels of Bcl-2 compared to normal lymphoid progenitor cells in the bone marrow and thymus. 33 Recent studies have demonstrated that Fas-mediated cell death involves activation of CPP32, which is a member of the interleukin-1␤ converting enzyme (ICE) family of cysteine proteases. 37, 38 Upon induction of apoptosis, the 32 kDa proenzyme CPP32 is cleaved into 11 kDa and 20 kDa proteins, which together form the active protease. The substrate for activated CPP32 has been identified as the protease poly (ADPribose) polymerase (PARP), which is involved in DNA repair and in the maintenance of genomic integrity. 39, 40 The cleavage of PARP to an 85-kDa fragment is an early event in apoptosis that may lead to inhibition of DNA repair, activation of endonuclease(s) and ultimately cell death. 41, 42 Bcl-2 appears to work upstream of CPP32 by preventing activation of this protease in response to apoptosis, thus inhibiting activation of CPP32 following Fas stimulation. 43, 44 Our findings are consistent with these previous results. As demonstrated by a functional assay, activation of CPP32 and apoptosis following treatment with anti-Fas failed to occur in Fas+ lines expressing high levels of Bcl-2 but were observed in all Fas+/Bcl-2− lines.
Our observation that some mt-p53+/Fas+ ALL cells are sensitive to treatment with anti-Fas antibody is of particular interest, since mt-p53+ cells are typically chemotherapy-and radiation-resistant. 45, 46 Although the p53 mutation is relatively infrequent in pediatric ALL cases at diagnosis, the incidence of p53 mutation tends to increase at relapse and is closely associated with refractory disease. 47, 48 In the present study, we were able to study primary, diagnostic specimens from two patients with mutations in p53/codon 248 from whom Fas+ cell lines (EU-10 and EU-11) were established; both patients had refractory disease and failed induction therapy. Primary leukemic cells from these patients were Fas+/Bcl-2-and sensitive to Fas, as were the derived cell lines. A third patient's primary leukemic cells were wt-p53+ and Fas+ but expressed high levels of Bcl-2 and were resistant to Fas. Results of these studies, as well as studies of primary cells from two additional patients, were consistent with results from the derived cell lines, suggesting that primary Fas+/mt-p53+/Bcl-2− cells are sensitive to treatment with anti-Fas antibody, while Fas+/wtp53+/Bcl-2+ cells are resistant.
In conclusion, we have for the first time detected an association in pediatric ALL between a mt-p53+/Bcl-2-phenotype, elevated expression of Fas, and sensitivity to Fas-mediated apoptosis. Further study will be required to determine if certain types of p53 mutations, such as the codon 248 mutation observed in the majority of these lines, predispose ALL cells to increased susceptibility to Fas relative to mutations at other loci (eg codon 273). However, taken together with our earlier finding that Bcl-2 is generally not expressed in mt-p53+ ALL cells, our results suggest that molecular methods for activation of Fas may be useful for the therapy of refractory Fas+/mtp53+ ALL.
